Morphic (MORF) Stock Forecast, Price Target & Predictions

MORF Stock Forecast

Morphic stock forecast is as follows: an average price target of $57.00 (represents a 0.02% upside from MORF’s last price of $56.99) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.

MORF Price Target

The average price target for Morphic (MORF) is $57.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $57.00. This represents a potential 0.02% upside from MORF's last price of $56.99.

MORF Analyst Ratings

Hold

According to 6 Wall Street analysts, Morphic's rating consensus is 'Hold'. The analyst rating breakdown for MORF stock is 0 'Strong Buy' (0.00%), 1 'Buy' (16.67%), 5 'Hold' (83.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Morphic Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 22, 2024	Alex Thompson	Stifel Nicolaus	$57.00	$56.52	0.85%	0.02%
Jul 13, 2024	Michael Yee	Jefferies	$57.00	$55.78	2.19%	0.02%
Jul 08, 2024	Edward Nash	Canaccord Genuity	$57.00	$55.74	2.26%	0.02%
Mar 13, 2024	Michael Yee	Jefferies	$60.00	$34.60	73.41%	5.28%

The latest Morphic stock forecast, released on Jul 22, 2024 by Alex Thompson from Stifel Nicolaus, set a price target of $57.00, which represents a 0.85% increase from the stock price at the time of the forecast ($56.52), and a 0.02% increase from MORF last price ($56.99).

Morphic Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$57.75
Last Closing Price	$56.99	$56.99	$56.99
Upside/Downside	-100.00%	-100.00%	1.33%

In the current month, the average price target of Morphic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Morphic's last price of $56.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jul 13, 2024	Jefferies		Hold	Downgrade
Jul 09, 2024	Cowen & Co.		Hold	Downgrade
Jul 09, 2024	RBC Capital	Outperform	Sector Perform	Downgrade
Jul 08, 2024	BMO Capital		Market Perform	Downgrade
Sep 25, 2023	Needham		Hold	Initialise
Feb 25, 2022	RBC Capital	Outperform	Outperform	Hold
Mar 07, 2021	Wells Fargo	Overweight	Overweight	Hold

Morphic's last stock rating was published by Jefferies on Jul 13, 2024. The company Downgrade its MORF rating from "null" to "Hold".

Morphic Financial Forecast

Morphic Revenue Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Revenue	-	-	-	-	-	-	$521.00K	$6.13M	$2.06M	$60.24M	$2.38M	$9.56M	$3.12M	$3.85M	$3.27M	$5.90M	$25.76M	$7.69M	$5.59M	$-334.00K	$5.67M	$5.57M
Avg Forecast	$750.00K	$250.00K	-	$1.98M	$1.33M	$2.40M	$2.16M	$3.04M	$3.48M	$3.65M	$3.75M	$14.86M	$5.19M	$5.80M	$7.83M	$6.62M	$12.30M	$5.57M	$4.47M	$5.77M	$5.03M	$470.78K
High Forecast	$750.00K	$250.00K	-	$2.38M	$1.33M	$2.40M	$2.16M	$3.04M	$3.48M	$3.65M	$3.75M	$14.86M	$5.19M	$5.80M	$7.83M	$6.62M	$12.30M	$5.57M	$4.47M	$5.77M	$5.03M	$564.94K
Low Forecast	$750.00K	$250.00K	-	$1.58M	$1.33M	$2.40M	$2.16M	$3.04M	$3.48M	$3.65M	$3.75M	$14.86M	$5.19M	$5.80M	$7.83M	$6.62M	$12.30M	$5.57M	$4.47M	$5.77M	$5.03M	$376.62K
# Analysts	1	1	-	18	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	8
Surprise %	-	-	-	-	-	-	0.24%	2.02%	0.59%	16.48%	0.63%	0.64%	0.60%	0.66%	0.42%	0.89%	2.09%	1.38%	1.25%	-0.06%	1.13%	11.83%

Morphic's average Quarter revenue forecast for Jun 23 based on 5 analysts is $2.40M, with a low forecast of $2.40M, and a high forecast of $2.40M. MORF's average Quarter revenue forecast represents a 361.46% increase compared to the company's last Quarter revenue of $521.00K (Mar 23).

Morphic EBITDA Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	-	18	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	8
EBITDA	-	-	-	-	$-44.75M	-	$-39.20M	$-26.34M	$-31.24M	$26.60M	$-31.41M	$-20.42M	$-24.72M	$-27.53M	$-21.00M	$-17.51M	$5.75M	$-15.32M	$-15.73M	$-18.15M	$-8.35M	$-9.10M
Avg Forecast	$-734.30K	$-244.77K	-	$-25.79M	$-1.31M	$-2.35M	$-27.58M	$-15.59M	$-3.41M	$-3.58M	$-29.50M	$-14.55M	$-5.08M	$-5.68M	$-17.95M	$-6.48M	$-12.04M	$-5.46M	$-13.44M	$-5.65M	$-4.92M	$-80.46M
High Forecast	$-734.30K	$-244.77K	-	$-20.63M	$-1.31M	$-2.35M	$-22.07M	$-12.47M	$-3.41M	$-3.58M	$-23.60M	$-14.55M	$-5.08M	$-5.68M	$-14.36M	$-6.48M	$-12.04M	$-5.46M	$-10.75M	$-5.65M	$-4.92M	$-64.37M
Low Forecast	$-734.30K	$-244.77K	-	$-30.95M	$-1.31M	$-2.35M	$-33.10M	$-18.71M	$-3.41M	$-3.58M	$-35.40M	$-14.55M	$-5.08M	$-5.68M	$-21.53M	$-6.48M	$-12.04M	$-5.46M	$-16.13M	$-5.65M	$-4.92M	$-96.55M
Surprise %	-	-	-	-	34.28%	-	1.42%	1.69%	9.16%	-7.43%	1.06%	1.40%	4.86%	4.85%	1.17%	2.70%	-0.48%	2.81%	1.17%	3.21%	1.70%	0.11%

3 analysts predict MORF's average Quarter EBITDA for Sep 22 to be $-3.41M, with a high of $-3.41M and a low of $-3.41M. This is -112.82% lower than Morphic's previous annual EBITDA (Jun 22) of $26.60M.

Morphic Net Income Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	-	18	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	8
Net Income	-	-	-	-	$-36.21M	-	$-36.13M	$-24.38M	$-30.02M	$26.84M	$-31.30M	$-21.97M	$-25.04M	$-27.82M	$-21.28M	$-17.75M	$5.35M	$-15.86M	$-16.75M	$-19.83M	$-8.86M	$-9.43M
Avg Forecast	$-50.60M	$-46.92M	$-50.10M	$-26.16M	$-47.77M	$-43.69M	$-27.98M	$-16.34M	$-41.58M	$-42.27M	$-29.93M	$-24.63M	$-36.37M	$-27.35M	$-18.19M	$-25.05M	$-21.44M	$-28.05M	$-14.30M	$-20.16M	$-19.91M	$-83.41M
High Forecast	$-50.60M	$-40.34M	$-50.10M	$-20.93M	$-41.24M	$-43.69M	$-22.39M	$-13.07M	$-41.58M	$-42.27M	$-23.94M	$-24.63M	$-36.37M	$-27.35M	$-14.55M	$-25.05M	$-21.44M	$-28.05M	$-11.44M	$-20.16M	$-19.91M	$-66.73M
Low Forecast	$-50.60M	$-52.62M	$-50.10M	$-31.40M	$-58.34M	$-43.69M	$-33.58M	$-19.60M	$-41.58M	$-42.27M	$-35.92M	$-24.63M	$-36.37M	$-27.35M	$-21.83M	$-25.05M	$-21.44M	$-28.05M	$-17.16M	$-20.16M	$-19.91M	$-100.09M
Surprise %	-	-	-	-	0.76%	-	1.29%	1.49%	0.72%	-0.64%	1.05%	0.89%	0.69%	1.02%	1.17%	0.71%	-0.25%	0.57%	1.17%	0.98%	0.45%	0.11%

Morphic's average Quarter net income forecast for Sep 22 is $-41.58M, with a range of $-41.58M to $-41.58M. MORF's average Quarter net income forecast represents a -254.91% decrease compared to the company's last Quarter net income of $26.84M (Jun 22).

Morphic SG&A Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	-	18	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	8
SG&A	-	-	-	-	$10.38M	-	$9.28M	$8.01M	$8.30M	$8.23M	$7.59M	$7.44M	$7.28M	$7.14M	$5.95M	$5.13M	$4.75M	$4.20M	$4.42M	$3.43M	$2.90M	$2.08M
Avg Forecast	$11.61M	$3.87M	-	$30.64M	$20.64M	$37.21M	$33.41M	$47.06M	$53.92M	$56.56M	$58.10M	$230.00M	$80.34M	$89.78M	$5.09M	$102.46M	$190.38M	$86.27M	$3.78M	$89.26M	$77.78M	$7.29M
High Forecast	$11.61M	$3.87M	-	$36.77M	$20.64M	$37.21M	$33.41M	$47.06M	$53.92M	$56.56M	$58.10M	$230.00M	$80.34M	$89.78M	$6.10M	$102.46M	$190.38M	$86.27M	$4.53M	$89.26M	$77.78M	$8.74M
Low Forecast	$11.61M	$3.87M	-	$24.51M	$20.63M	$37.21M	$33.41M	$47.06M	$53.92M	$56.56M	$58.10M	$230.00M	$80.34M	$89.78M	$4.07M	$102.46M	$190.38M	$86.27M	$3.02M	$89.26M	$77.78M	$5.83M
Surprise %	-	-	-	-	0.50%	-	0.28%	0.17%	0.15%	0.15%	0.13%	0.03%	0.09%	0.08%	1.17%	0.05%	0.02%	0.05%	1.17%	0.04%	0.04%	0.29%

Morphic's average Quarter SG&A projection for Mar 24 is $30.64M, based on 18 Wall Street analysts, with a range of $24.51M to $36.77M. The forecast indicates a 195.07% rise compared to MORF last annual SG&A of $10.38M (Sep 23).

Morphic EPS Forecast

	Dec 24	Sep 24	Jun 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
# Analysts	1	1	-	18	8	5	4	4	3	4	3	5	4	5	4	5	4	5	4	4	3	8
EPS	-	-	-	-	$-0.74	-	$-0.90	$-0.64	$-0.78	$0.70	$-0.84	$-0.60	$-0.69	$-0.77	$-0.63	$-0.58	$0.18	$-0.52	$-0.55	$-0.66	$-0.30	$-4.73
Avg Forecast	$-1.01	$-0.94	$-1.00	$-0.94	$-0.95	$-0.87	$-0.81	$-0.87	$-0.83	$-0.84	$-0.81	$-0.49	$-0.73	$-0.55	$-0.55	$-0.50	$-0.43	$-0.56	$-0.48	$-0.40	$-0.40	$-3.54
High Forecast	$-1.01	$-0.81	$-1.00	$-0.94	$-0.82	$-0.87	$-0.81	$-0.87	$-0.83	$-0.84	$-0.81	$-0.49	$-0.73	$-0.55	$-0.55	$-0.50	$-0.43	$-0.56	$-0.48	$-0.40	$-0.40	$-2.83
Low Forecast	$-1.01	$-1.05	$-1.00	$-0.94	$-1.16	$-0.87	$-0.81	$-0.87	$-0.83	$-0.84	$-0.81	$-0.49	$-0.73	$-0.55	$-0.55	$-0.50	$-0.43	$-0.56	$-0.48	$-0.40	$-0.40	$-4.24
Surprise %	-	-	-	-	0.78%	-	1.11%	0.73%	0.94%	-0.83%	1.04%	1.22%	0.95%	1.41%	1.15%	1.16%	-0.42%	0.93%	1.15%	1.63%	0.75%	1.34%

According to 3 Wall Street analysts, Morphic's projected average Quarter EPS for Sep 22 is $-0.83, with a low estimate of $-0.83 and a high estimate of $-0.83. This represents a -218.57% decrease compared to MORF previous annual EPS of $0.70 (Jun 22).

Morphic Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$2.37	$33.86	1328.69%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
IMCR	Immunocore	$29.40	$70.20	138.78%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
VKTX	Viking Therapeutics	$46.70	$97.80	109.42%	Buy
RNA	Avidity Biosciences	$32.74	$59.00	80.21%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
AKRO	Akero Therapeutics	$30.61	$50.00	63.35%	Buy
ETNB	89bio	$7.98	$12.00	50.38%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
PTGX	Protagonist Therapeutics	$40.69	$57.33	40.89%	Buy
ACLX	Arcellx	$82.03	$111.60	36.05%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy

MORF Forecast FAQ

Is Morphic a good buy?

No, according to 6 Wall Street analysts, Morphic (MORF) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 16.67% of MORF's total ratings.

What is MORF's price target?

Morphic (MORF) average price target is $57 with a range of $57 to $57, implying a 0.02% from its last price of $56.99. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Morphic stock go up soon?

According to Wall Street analysts' prediction for MORF stock, the company can go up by 0.02% (from the last price of $56.99 to the average price target of $57), up by 0.02% based on the highest stock price target, and up by 0.02% based on the lowest stock price target.

Can Morphic stock reach $90?

MORF's average twelve months analyst stock price target of $57 does not support the claim that Morphic can reach $90 in the near future.

What are Morphic's analysts' financial forecasts?

MORF's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.98M (high $3.38M, low $2.58M), average EBITDA is $-26.77M (high $-21.612M, low $-31.928M), average net income is $-174M (high $-162M, low $-185M), average SG&A $46.12M (high $52.25M, low $39.99M), and average EPS is $-3.888 (high $-3.756, low $-4.001).

Did the MORF's actual financial results beat the analysts' financial forecasts?

Based on Morphic's last annual report (Dec 2022), the company's revenue was $70.81M, beating the average analysts forecast of $13.93M by 408.23%. Apple's EBITDA was $-63.396M, beating the average prediction of $-52.079M by 21.73%. The company's net income was $-59.041M, missing the average estimation of $-130M by -54.62%. Apple's SG&A was $32.14M, missing the average forecast of $215.64M by -85.09%. Lastly, the company's EPS was $-1.55, missing the average prediction of $-3.358 by -53.83%. In terms of the last quarterly report (Mar 2023), Morphic's revenue was $521K, missing the average analysts' forecast of $2.16M by -75.87%. The company's EBITDA was $-39.205M, beating the average prediction of $-27.584M by 42.13%. Morphic's net income was $-36.135M, beating the average estimation of $-27.984M by 29.13%. The company's SG&A was $9.28M, missing the average forecast of $33.41M by -72.24%. Lastly, the company's EPS was $-0.9, beating the average prediction of $-0.81 by 11.11%